Summer is here and with it a chance to reflect on a very productive last six months that culminated with the release of our the release of the 26^th edition of Ernst & Young’s Biotechnology Industry Annual Report, Beyond Borders, at the BIO International Convention on June 17.  Beyond Borders came together later this year, in part because our team needed to catch its collective breath after the February release of Beyond Borders sister publication, Progressions.  While we were still fortunate enough to have contributions from many industry executives and investors – including Moncef Slaoui, Chairman R&D at GlaxoSmithKline, and Tony Coles, CEO of Onyx Pharmaceuticals - we had far less of an opportunity to “test and validate” our points of view with market participants as they were evolving.  As such, it was particularly gratifying that the key themes of the year’s report – how biopharmaceutical R&D needs a new model, based on holistic collaboration between players from across the healthcare ecosystem and perhaps beyond – was very aligned with many  of the panel discussions and hallway conversations at BIO.  As one of SuperSession panelists, Joshua Boger, put it – we seemed to have “captured a bit of the meeting zeitgeist.”

I will be blogging about Holistic, Open, Learning Networks (or what we call HOLNets), and how models based on these principals could transform the way R&D is conducted in the biopharmaceutical industry today in future posts – both here and on a blog on Ernst & Young’s Life Sciences webpage which is launching later this month (www.ey.com/lifesciences).  

For now here are some links:

www.ey.com/bb12

 

The media release which summarizes key findings is here

An interview I did at BIO with Chris Morrison of Elsevier and the InVivo Blog on the HOLNet concept is here